United States Neurological Disorder Drugs Market Report 2017

United States Neurological Disorder Drugs Market Report 2017

1 Neurological Disorder Drugs Overview

1.1 Product Overview and Scope of Neurological Disorder Drugs

1.2 Classification of Neurological Disorder Drugs by Product Category

1.2.1 United States Neurological Disorder Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)

1.2.2 United States Neurological Disorder Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016

1.2.3 Antipsychotic

1.2.4 Hypnotic & Sedative

1.2.5 Analgesics

1.2.6 Anticoagulants

1.2.7 Others

1.3 United States Neurological Disorder Drugs Market by Application/End Users

1.3.1 United States Neurological Disorder Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Home

1.4 United States Neurological Disorder Drugs Market by Region

1.4.1 United States Neurological Disorder Drugs Market Size (Value) Comparison by Region (2012-2022)

1.4.2 The West Neurological Disorder Drugs Status and Prospect (2012-2022)

1.4.3 Southwest Neurological Disorder Drugs Status and Prospect (2012-2022)

1.4.4 The Middle Atlantic Neurological Disorder Drugs Status and Prospect (2012-2022)

1.4.5 New England Neurological Disorder Drugs Status and Prospect (2012-2022)

1.4.6 The South Neurological Disorder Drugs Status and Prospect (2012-2022)

1.4.7 The Midwest Neurological Disorder Drugs Status and Prospect (2012-2022)

1.5 United States Market Size (Value and Volume) of Neurological Disorder Drugs (2012-2022)

1.5.1 United States Neurological Disorder Drugs Sales and Growth Rate (2012-2022)

1.5.2 United States Neurological Disorder Drugs Revenue and Growth Rate (2012-2022)

2 United States Neurological Disorder Drugs Market Competition by Players/Suppliers

2.1 United States Neurological Disorder Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)

2.2 United States Neurological Disorder Drugs Revenue and Share by Players/Suppliers (2012-2017)

2.3 United States Neurological Disorder Drugs Average Price by Players/Suppliers (2012-2017)

2.4 United States Neurological Disorder Drugs Market Competitive Situation and Trends

2.4.1 United States Neurological Disorder Drugs Market Concentration Rate

2.4.2 United States Neurological Disorder Drugs Market Share of Top 3 and Top 5 Players/Suppliers

2.4.3 Mergers & Acquisitions, Expansion in United States Market

2.5 United States Players/Suppliers Neurological Disorder Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Neurological Disorder Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)

3.1 United States Neurological Disorder Drugs Sales and Market Share by Region (2012-2017)

3.2 United States Neurological Disorder Drugs Revenue and Market Share by Region (2012-2017)

3.3 United States Neurological Disorder Drugs Price by Region (2012-2017)

4 United States Neurological Disorder Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)

4.1 United States Neurological Disorder Drugs Sales and Market Share by Type (Product Category) (2012-2017)

4.2 United States Neurological Disorder Drugs Revenue and Market Share by Type (2012-2017)

4.3 United States Neurological Disorder Drugs Price by Type (2012-2017)

4.4 United States Neurological Disorder Drugs Sales Growth Rate by Type (2012-2017)

5 United States Neurological Disorder Drugs Sales (Volume) by Application (2012-2017)

5.1 United States Neurological Disorder Drugs Sales and Market Share by Application (2012-2017)

5.2 United States Neurological Disorder Drugs Sales Growth Rate by Application (2012-2017)

5.3 Market Drivers and Opportunities

6 United States Neurological Disorder Drugs Players/Suppliers Profiles and Sales Data

6.1 Novartis AG

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Neurological Disorder Drugs Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Novartis AG Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 GlaxoSmithKline plc

6.2.2 Neurological Disorder Drugs Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 GlaxoSmithKline plc Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 Merck & Co.

6.3.2 Neurological Disorder Drugs Product Category, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Merck & Co. Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

6.4 Bayer AG

6.4.2 Neurological Disorder Drugs Product Category, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Bayer AG Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

6.5 AstraZeneca

6.5.2 Neurological Disorder Drugs Product Category, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 AstraZeneca Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Main Business/Business Overview

6.6 Boehringer Ingelheim GmbH

6.6.2 Neurological Disorder Drugs Product Category, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Main Business/Business Overview

6.7 Teva Pharmaceutical Industries Ltd.

6.7.2 Neurological Disorder Drugs Product Category, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 Teva Pharmaceutical Industries Ltd. Neurological Disorder Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.7.4 Main Business/Business Overview

...

7 Neurological Disorder Drugs Manufacturing Cost Analysis

7.1 Neurological Disorder Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Neurological Disorder Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers

8.1 Neurological Disorder Drugs Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Neurological Disorder Drugs Major Manufacturers in 2016

8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List

10 Market Effect Factors Analysis

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

11 United States Neurological Disorder Drugs Market Size (Value and Volume) Forecast (2017-2022)

11.1 United States Neurological Disorder Drugs Sales Volume, Revenue Forecast (2017-2022)

11.2 United States Neurological Disorder Drugs Sales Volume Forecast by Type (2017-2022)

11.3 United States Neurological Disorder Drugs Sales Volume Forecast by Application (2017-2022)

11.4 United States Neurological Disorder Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

Figure Product Picture of Neurological Disorder Drugs

Figure United States Neurological Disorder Drugs Market Size (K Pcs) by Type (2012-2022)

Figure United States Neurological Disorder Drugs Sales Volume Market Share by Type (Product Category) in 2016

Figure Antipsychotic Product Picture

Figure Hypnotic & Sedative Product Picture

Figure Analgesics Product Picture

Figure Anticoagulants Product Picture

Figure Others Product Picture

Figure United States Neurological Disorder Drugs Market Size (K Pcs) by Application (2012-2022)

Figure United States Sales Market Share of Neurological Disorder Drugs by Application in 2016

Figure Hospital Examples

Table Key Downstream Customer in Hospital

Figure Clinic Examples

Table Key Downstream Customer in Clinic

Figure Home Examples

Table Key Downstream Customer in Home

Figure United States Neurological Disorder Drugs Market Size (Million USD) by Region (2012-2022)

Figure The West Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure Southwest Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The Middle Atlantic Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure New England Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The South of US Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The Midwest Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure United States Neurological Disorder Drugs Sales (K Pcs) and Growth Rate (2012-2022)

Figure United States Neurological Disorder Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure United States Neurological Disorder Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)

Table United States Neurological Disorder Drugs Sales (K Pcs) of Key Players/Suppliers (2012-2017)

Table United States Neurological Disorder Drugs Sales Share by Players/Suppliers (2012-2017)

Figure 2016 United States Neurological Disorder Drugs Sales Share by Players/Suppliers

Figure 2017 United States Neurological Disorder Drugs Sales Share by Players/Suppliers

Figure United States Neurological Disorder Drugs Market Major Players Product Revenue (Million USD) (2012-2017)

Table United States Neurological Disorder Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)

Table United States Neurological Disorder Drugs Revenue Share by Players/Suppliers (2012-2017)

Figure 2016 United States Neurological Disorder Drugs Revenue Share by Players/Suppliers

Figure 2017 United States Neurological Disorder Drugs Revenue Share by Players/Suppliers

Table United States Market Neurological Disorder Drugs Average Price (USD/Pcs) of Key Players/Suppliers (2012-2017)

Figure United States Market Neurological Disorder Drugs Average Price (USD/Pcs) of Key Players/Suppliers in 2016

Figure United States Neurological Disorder Drugs Market Share of Top 3 Players/Suppliers

Figure United States Neurological Disorder Drugs Market Share of Top 5 Players/Suppliers

Table United States Players/Suppliers Neurological Disorder Drugs Manufacturing Base Distribution and Sales Area

Table United States Players/Suppliers Neurological Disorder Drugs Product Category

Table United States Neurological Disorder Drugs Sales (K Pcs) by Region (2012-2017)

Table United States Neurological Disorder Drugs Sales Share by Region (2012-2017)

Figure United States Neurological Disorder Drugs Sales Share by Region (2012-2017)

Figure United States Neurological Disorder Drugs Sales Market Share by Region in 2016

Table United States Neurological Disorder Drugs Revenue (Million USD) and Market Share by Region (2012-2017)

Table United States Neurological Disorder Drugs Revenue Share by Region (2012-2017)

Figure United States Neurological Disorder Drugs Revenue Market Share by Region (2012-2017)

Figure United States Neurological Disorder Drugs Revenue Market Share by Region in 2016

Table United States Neurological Disorder Drugs Price (USD/Pcs) by Region (2012-2017)

Table United States Neurological Disorder Drugs Sales (K Pcs) by Type (2012-2017)

Table United States Neurological Disorder Drugs Sales Share by Type (2012-2017)

Figure United States Neurological Disorder Drugs Sales Share by Type (2012-2017)

Figure United States Neurological Disorder Drugs Sales Market Share by Type in 2016

Table United States Neurological Disorder Drugs Revenue (Million USD) and Market Share by Type (2012-2017)

Table United States Neurological Disorder Drugs Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Neurological Disorder Drugs by Type (2012-2017)

Figure Revenue Market Share of Neurological Disorder Drugs by Type in 2016

Table United States Neurological Disorder Drugs Price (USD/Pcs) by Types (2012-2017)

Figure United States Neurological Disorder Drugs Sales Growth Rate by Type (2012-2017)

Table United States Neurological Disorder Drugs Sales (K Pcs) by Application (2012-2017)

Table United States Neurological Disorder Drugs Sales Market Share by Application (2012-2017)

Figure United States Neurological Disorder Drugs Sales Market Share by Application (2012-2017)

Figure United States Neurological Disorder Drugs Sales Market Share by Application in 2016

Table United States Neurological Disorder Drugs Sales Growth Rate by Application (2012-2017)

Figure United States Neurological Disorder Drugs Sales Growth Rate by Application (2012-2017)

Table Novartis AG Basic Information List

Table Novartis AG Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Novartis AG Neurological Disorder Drugs Sales Growth Rate (2012-2017)

Figure Novartis AG Neurological Disorder Drugs Sales Market Share in United States (2012-2017)

Figure Novartis AG Neurological Disorder Drugs Revenue Market Share in United States (2012-2017)

Table GlaxoSmithKline plc Basic Information List

Table GlaxoSmithKline plc Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure GlaxoSmithKline plc Neurological Disorder Drugs Sales Growth Rate (2012-2017)

Figure GlaxoSmithKline plc Neurological Disorder Drugs Sales Market Share in United States (2012-2017)

Figure GlaxoSmithKline plc Neurological Disorder Drugs Revenue Market Share in United States (2012-2017)

Table Merck & Co. Basic Information List

Table Merck & Co. Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Merck & Co. Neurological Disorder Drugs Sales Growth Rate (2012-2017)

Figure Merck & Co. Neurological Disorder Drugs Sales Market Share in United States (2012-2017)

Figure Merck & Co. Neurological Disorder Drugs Revenue Market Share in United States (2012-2017)

Table Bayer AG Basic Information List

Table Bayer AG Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Bayer AG Neurological Disorder Drugs Sales Growth Rate (2012-2017)

Figure Bayer AG Neurological Disorder Drugs Sales Market Share in United States (2012-2017)

Figure Bayer AG Neurological Disorder Drugs Revenue Market Share in United States (2012-2017)

Table AstraZeneca Basic Information List

Table AstraZeneca Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure AstraZeneca Neurological Disorder Drugs Sales Growth Rate (2012-2017)

Figure AstraZeneca Neurological Disorder Drugs Sales Market Share in United States (2012-2017)

Figure AstraZeneca Neurological Disorder Drugs Revenue Market Share in United States (2012-2017)

Table Boehringer Ingelheim GmbH Basic Information List

Table Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales Growth Rate (2012-2017)

Figure Boehringer Ingelheim GmbH Neurological Disorder Drugs Sales Market Share in United States (2012-2017)

Figure Boehringer Ingelheim GmbH Neurological Disorder Drugs Revenue Market Share in United States (2012-2017)

Table Teva Pharmaceutical Industries Ltd. Basic Information List

Table Teva Pharmaceutical Industries Ltd. Neurological Disorder Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)

Figure Teva Pharmaceutical Industries Ltd. Neurological Disorder Drugs Sales Growth Rate (2012-2017)

Figure Teva Pharmaceutical Industries Ltd. Neurological Disorder Drugs Sales Market Share in United States (2012-2017)

Figure Teva Pharmaceutical Industries Ltd. Neurological Disorder Drugs Revenue Market Share in United States (2012-2017)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Neurological Disorder Drugs

Figure Manufacturing Process Analysis of Neurological Disorder Drugs

Figure Neurological Disorder Drugs Industrial Chain Analysis

Table Raw Materials Sources of Neurological Disorder Drugs Major Players/Suppliers in 2016

Table Major Buyers of Neurological Disorder Drugs

Table Distributors/Traders List

Figure United States Neurological Disorder Drugs Sales Volume (K Pcs) and Growth Rate Forecast (2017-2022)

Figure United States Neurological Disorder Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure United States Neurological Disorder Drugs Price (USD/Pcs) Trend Forecast (2017-2022)

Table United States Neurological Disorder Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)

Figure United States Neurological Disorder Drugs Sales Volume (K Pcs) Forecast by Type (2017-2022)

Figure United States Neurological Disorder Drugs Sales Volume (K Pcs) Forecast by Type in 2022

Table United States Neurological Disorder Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)

Figure United States Neurological Disorder Drugs Sales Volume (K Pcs) Forecast by Application (2017-2022)

Figure United States Neurological Disorder Drugs Sales Volume (K Pcs) Forecast by Application in 2022

Table United States Neurological Disorder Drugs Sales Volume (K Pcs) Forecast by Region (2017-2022)

Table United States Neurological Disorder Drugs Sales Volume Share Forecast by Region (2017-2022)

Figure United States Neurological Disorder Drugs Sales Volume Share Forecast by Region (2017-2022)

Figure United States Neurological Disorder Drugs Sales Volume Share Forecast by Region in 2022

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources